Carl Zeiss Meditec Community
XTRA:AFX Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 40 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 16 Analysts
VISUMAX 800 Approval In China Will Strengthen Future Market Position
Key Takeaways Early VISUMAX 800 approval in China and strong order backlog for KINEVO 900 S hint at significant future revenue growth. Shift towards premium IOLs and effective cost measures promise higher net margins and earnings stability.
View narrative€61.22
FV
3.2% undervalued intrinsic discount7.44%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
22users have followed this narrative
6 days ago author updated this narrative